Similar articles

• Functional properties of RYR1 mutations identified in Swedish patients with malignant hyperthermia and central core disease.

  Vukcevic M, Broman M, Islander G, Bodelsson M, Ranklev-Twetman E, Müller CR, Treves S. Vukcevic M, et al. Anesth Analg. 2010 Jul;111(1):185-90. doi: 10.1213/ANE.0b013e3181cbd815. Epub 2010 Feb 8. Anesth Analg. 2010. PMID: 20142353
• Functional studies of RYR1 mutations in the skeletal muscle ryanodine receptor using human RYR1 complementary DNA.

  Sato K, Pollock N, Stowell KM. Sato K, et al. Anesthesiology. 2010 Jun;112(6):1350-4. doi: 10.1097/ALN.0b013e3181d69283. Anesthesiology. 2010. PMID: 20461000
• Identification of a novel mutation in the ryanodine receptor gene (RYR1) in patients with malignant hyperthermia.

  Rueffert H, Kraus H, Olthoff D, Deutrich C, Froster UG. Rueffert H, et al. Hum Mutat. 2001 Mar;17(3):238. doi: 10.1002/humu.15. Hum Mutat. 2001. PMID: 11241852 No abstract available.
• Ryanodine receptor mutations in malignant hyperthermia and central core disease.

  McCarthy TV, Quane KA, Lynch PJ. McCarthy TV, et al. Hum Mutat. 2000;15(5):410-7. doi: 10.1002/(SICI)1098-1004(200005)15:5<410::AID-HUMU2>3.0.CO;2-D. Hum Mutat. 2000. PMID: 10790202 Review.
• Multiminicore myopathy, central core disease, malignant hyperthermia susceptibility, and RYR1 mutations: one disease with many faces?

  Mathews KD, Moore SA. Mathews KD, et al. Arch Neurol. 2004 Jan;61(1):27-9. doi: 10.1001/archneur.61.1.27. Arch Neurol. 2004. PMID: 14732615 Review. No abstract available.